YYC405
/ Yooyoung Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 01, 2022
Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
(clinicaltrials.gov)
- P3 | N=256 | Active, not recruiting | Sponsor: Yooyoung Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 1
Of
1
Go to page
1